Evidence map›Paper›PMID 42458409›Full record

ArticleBMC endocrine disorders2026

Role of sRAGE in clinical heterogeneity and inflammation in endometriosis patients undergoing IVF; case-control study.

Neda Emami, Ashraf Moini

Abstract read
In one paragraph

Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Neda EmamiDepartment of Gynecology and Obstetrics, Tehran University of Medical Sciences, Tehran, Iran. Neda.Emami58@gmail.com.
Ashraf MoiniDepartment of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndometriosis is a multifactorial, chronic inflammatory disorder that affects a substantial proportion of women during their reproductive years and is frequently associated with pelvic pain and infertility. Accumulating evidence suggests that advanced glycation end products (AGEs), generated through dietary exposure and oxidative stress, may contribute to disease progression by activating the receptor for AGEs (RAGE), thereby promoting inflammatory and fibrotic signaling pathways. Rather than serving as an initiating factor, the AGE-RAGE axis is increasingly recognized as an amplifier of persistent inflammation and lesion persistence in endometriosis. The soluble isoform of RAGE (sRAGE) acts as a circulating decoy receptor that sequesters AGEs and attenuates downstream pro-inflammatory cascades. Although dysregulated sRAGE concentrations have been documented in various metabolic and reproductive conditions, its specific role in endometriosis-particularly within the follicular microenvironment and in relation to inflammatory status-remains incompletely characterized.

methodsIn this prospective case-control study, 71 women of reproductive age undergoing controlled ovarian stimulation and oocyte retrieval for in vitro fertilization (IVF) were enrolled. The case group included 40 women with confirmed endometriosis, while 31 women without endometriosis served as controls. Detailed clinical histories were obtained for both groups. Serum and follicular fluid samples were collected, and sRAGE concentrations were quantified using enzyme-linked immunosorbent assay (ELISA).

resultsNo significant differences were observed between groups regarding age or body mass index. Both serum and follicular fluid sRAGE concentrations were significantly elevated in women with endometriosis compared with controls (both P < 0.001). Evaluation of clinical heterogeneity demonstrated significantly lower follicular fluid sRAGE levels among endometriosis women with concomitant allergic conditionsnull (P = 0.012). Within the endometriosis cohort, sRAGE concentrations did not vary significantly according to pain severity, including dysmenorrhea, pelvic pain, or dyspareunia. Likewise, no significant associations were identified with thyroid disorders, gastrointestinal disease, adenomyosis, migraine, asthma, diabetes, or multiple sclerosis. Furthermore, sRAGE levels were not correlated with the number of retrieved oocytes or embryos in either group.

conclusionWomen with endometriosis exhibited significantly elevated serum and follicular fluid sRAGE levels, suggesting altered AGE-RAGE axis activity. However, the absence of association with ovarian response indicates that sRAGE may reflect inflammatory status rather than reproductive outcomes.

Indexed as

BiomarkersEndometriosisFertilization in VitroInfertility, FemaleInflammationReceptor for Advanced Glycation End ProductsAdultCase-Control StudiesFemaleFollicular FluidFollow-Up StudiesGlycation End Products, AdvancedHumansPrognosisProspective StudiesBiomarkersGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsAdvanced glycation end productsBiomarkerEndometriosisInfertility signal transductionInflammation

Identifiers

PMID42458409
PMCPMC13656528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.